NGS-Based Clinical Testing: Part II

· Andreas Scherer · Big Picture, eBooks

We have come a long way since Next-Generation Sequencing (NGS) evolved as a set of technologies in the 1970s. The higher throughput and rapid reduction of costs associated with NGS have lead to the accelerated adoption of clinical testing that we are experiencing today. Currently, it is applied to analyze inherited diseases, tumors, hematologic malignancies and infectious diseases. It is also used in noninvasive prenatal screening to detect fetal chromosome defects. This just names a few focus areas utilizing NGS.

NGS-based testing represents a still evolving technology. Improvements in areas such as instrumentation, sequencing, chemistry and bioinformatic analysis are frequently common. Faced with the reality that this continuously advancing set of technologies is being widely adopted in laboratories nationwide, the College of American Pathologists (CAP) has formed a committee. The NGS Work Group is a committee which oversees the standards development providing the necessary regulatory framework without inhibiting the adoption of this new paradigm.

Next-generation sequencing is essentially comprised of two processes:

1. The analytic wet bench process. This includes the handling of patient samples, extracting nucleic acids, fragmentation, molecular indexing (barcoding), target enrichment, adapter ligation, amplification, library preparation and generation of sequencing reads.

2. The bioinformatics analysis of DNA sequences. This includes aligning the sequencing reads to a linear human reference genome sequence. After that, variants are called where certain nucleotides in the patient sample sequence are different from the reference sequence. Finally, the most important variant filtering and interpretation stage occurs where the variants vis a vis the clinically observed phenotype are analyzed.

The CAP NGS Work Group approached both areas as two separate, discreet processes requiring a different set of standards. As a result, we have well-defined accreditation checklist of requirements for both processes that have been incorporated within the CAP’s molecular pathology checklist (MOL)…

To continue reading, I invite you to download a complimentary copy of this eBook below:

2 Comments

Leave a comment

Andreas Scherer

About Andreas Scherer

Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing. With its solutions, hundreds of the world’s hospitals and testing labs are able to harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. Golden Helix is also on the Inc 5000 list of the fastest-growing private companies in the US. He is also Managing Partner of Salto Partners, Inc, a management consulting firm headquartered in Nevada.  He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales, and operations. Clients are operating in the high-tech and life sciences space. Dr. Scherer holds a Ph.D. in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! 

View all posts by Andreas Scherer →